Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996407 | 0.98 | BTK (0.36) | BTKKMT2ATSHR | |
| SCHEMBL5131640 | 0.98 | BTK (0.36) | BTKKMT2ATSHR | |
| SCHEMBL2712968 | 0.97 | TSHR (0.37) | BTKKMT2ATSHR | |
| SCHEMBL9744380 | 0.97 | TSHR (0.37) | BTKKMT2ATSHR | |
| SCHEMBL647264 | 0.97 | TSHR (0.37) | BTKKMT2ATSHR | |
| SCHEMBL4328796 | 0.97 | TSHR (0.37) | BTKKMT2ATSHR | |
| SCHEMBL9744375 | 0.97 | TSHR (0.37) | BTKKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL30546580 | 0.95 | TSHR (0.36) | BTKKMT2ATSHR | |
| SCHEMBL2350718 | 0.95 | KMT2A (0.34) | BTKKMT2AHRH3HSD11B1 | |
| SCHEMBL2350728 | 0.95 | KMT2A (0.34) | BTKKMT2AHRH3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165069-A | Nitrogen-containing spiro indoline compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2237793-A1 | INHIBITORS OF CATHEPSIN B | Virobay, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009100225-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | CTSB, CSTB, CTSF | BTK 4282/4885KMT2A 4689/4885TSHR 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.